The Food and Drug Administration has approved Moderna's mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at ...

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company’s approved respiratory ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals ...

I believe the sentiment around Moderna began to go from bearish to a mixed condition in June, after the company received FDA approval for their next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283).

The approval was based on data from an active-controlled Phase 3 clinical trial in which mNEXSPIKE generated a higher immune response against COVID-19 compared to Moderna’s (NASDAQ: MRNA ...

This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines.

The main side effects of mNEXSPIKE were injection site pain, fatigue, headache and muscle pain, Moderna said in its press release. This story first appeared on NBCNews.com. More from NBC News: ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

Meanwhile, Moderna scored an FDA nod for a next-generation COVID-19 vaccine, dubbed mNEXSPIKE, in June, but the green light came with restrictions.

This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines.